Congresses

 

We have included congress publications sponsored or supported by Roche/Genentech from mid-2019 onwards, including oral presentations and posters. If you would like access to a Roche or Genentech-supported congress poster or presentation from before that date, please contact your local company’s medical information representative. 

Congress materials related to Roche drugs presented at major International Scientific Congresses will be made available on this page at the end of the embargo and with the consent of the presenter.

Emicizumab Pediatric Experience in Clinical Studies and Beyond.

Invited oral presentation: Levy G.

Summary of thromboembolic (TE) or thrombotic microangiopathy (TMA) events in persons taking emicizumab.

Oral presentation P131: Lee L, Moreno K, Kuebler P, et al.

Low immunogenicity of emicizumab in persons with haemophilia A

Poster Presentation ABS141: Schmitt C, Emrich T, Asikanius E et al.

Emicizumab in Obese Adults with Hemophilia A – Pooled Data from Three Phase III Studies (HAVEN 1, 3 and 4)

Poster Presentation PB0495: Recht M, Mahlangu J, Minhas, et al

Bone and joint health markers in persons with hemophilia A treated with emicizumab in HAVEN 3.

Oral presentation: Kiialainen A, Niggli M, Kempton C, et al.

An Insight into Clinical Outcomes in Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study.

Oral presentation OC 09.3: Nissen F, Burke T, Asghar S, et al.

Effect of Moderate and Severe Hemophilia A on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis.

Oral Presentation: Khair K, Nissen F, Silkey M, et al.

Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies.

Oral presentation OC 60.2: Callaghan M, Negrier C, Paz-Priel I, et al.

Timing of Treated Spontaneous Bleeding in Persons with Haemophilia A Receiving Emicizumab Prophylaxis 6 mg/kg Once Every 4 Weeks.

Poster presentation P191: Pipe SW, Ko RH, Chang T, et al.

Safety and Efficacy of Emicizumab in Persons With Haemophilia A With / Without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4)

Poster Presentation ABS192: Callaghan MU, Négrier C, Paz-Priel I et al.

Association of Physical Activity with Bleeding Frequency in Children with Hemophilia A: A CHESS PAEDs Study Analysis

Poster Presentation PB0512: Ofori-Asenso R, Nissen F, Silkey M, et al

Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data.

Poster presentation P-1133: Faghmous I, Flores C, Sarouei K, et al.

Real-World Persistence With and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia A: a Secondary Claims Database Analysis.

Poster Presentation P-866: Mahajerin A, Khairnar R, Meyer CS, et al.

Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors.

Oral presentation OC 60.1: Santagostino E, Oldenburg J, Chang T, et al.

A Survey Study of Hematologists in the United States to Understand Disease Management of Patients with Hemophilia A Treated with Emicizumab.

Poster presentation P205: Owens WE, Patel AM, Poulos K, et al.

Evaluating the economic burden associated with problem joints, across moderate and severe haemophilia A, in children and adults: CHESS Paediatrics and CHESS II

Poster Presentation ABS1148: Chowdary P, Hermans C, Asghar S et al.

Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A with Factor VIII Inhibitors

Poster Presentation PB0521: Jiménez-Yuste V, Peyvandi F, Klamroth R, et al

Factor VIII use in the treatment of breakthrough bleeds in hemophilia A patients without inhibitors on emicizumab prophylaxis: the Phase 3 HAVEN 3 study experience.

Poster presentation P-2395: Callaghan M, Trzaskoma B, Ko RH, et al.

Surgical experience from the Phase III STASEY trial of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors: Data from the second interim analysis.

Poster presentation PB0939: Castaman G, Kremer Hovinga JA, Schutgens R, et al.

A Phase IV, Multicenter, Open-label Study of Emicizumab Prophylaxis in Persons with Hemophilia A with or Without FVIII Inhibitors Undergoing Minor Surgical Procedures.

Poster Presentation P-1786: Escobar M, Dunn A, Quon D, et al.

A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results.

Oral presentation OC 60.3: Jimenez-Yuste V, Klamroth R, Castaman G, et al.

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data.

Poster presentation P-2398: Mahajerin A, Patel AM, Yang E, et al.

Pharmacokinetics and coagulation biomarkers in persons with hemophilia A (PwHA) and FVIII inhibitors receiving emicizumab in the Phase IIIb STASEY study.

Poster presentation PB0942: Kiialainen A, Petry C, Jiménez-Yuste V, et al.

Analysis of Hemophilia A Outcomes and Treatment Patterns Using Real World Data From the Canadian Hemophilia Bleeding Disorder Registry.

Poster Presentation P-1793: Lee A, Germini F, Poon MC, et al.

Analytical performance evaluation of a dedicated calibrator and controls for emicizumab quantification.

Oral presentation OC 07.4: Ramamurthy N, Kucharski C, McInerney M, et al.

A randomized, multicenter, open-label, Phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-Pacific region (HAVEN 5).

Poster presentation PB0957: Wang S, Zhao X, Wang X, et al.

Safety and Efficacy of Emicizumab in Persons with Hemophilia A With or Without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4).

Poster Presentation P-1800: Callaghan M, Négrier C, Paz-Priel I, et al.

Joint bleeds in paediatric patients with haemophilia A: a CHESS study analysis.

Oral presentation OC 70.1: Castro FA, Silkey M, Khair K, et al.

Associations between physical activity levels and bleeding frequency in people with mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study.

Poster presentation PB0943: Nissen F, Burke T, Asghar S, et al.

Problem Joints and their Clinical and Humanistic Burden in Children and Adults with Moderate and Severe Hemophilia A: CHESS Paediatrics and CHESS II.

Poster Presentation P-2532: McLaughlin P, Hermans C, Asghar S, et al.

Timing of treated spontaneous bleeding in persons with haemophilia A (PwHA) in the HAVEN 3 study.

Poster presentation PB0694: Mahlangu J, Oldenburg J, O’Connell N, et al.

Real-World Safety of Emicizumab: The First Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database.

Poster Presentation P-2685: Shang A, Selak-Bienz N, Gadiraju R, et al.

Exposure–response modeling of emicizumab for the prophylaxis of bleeding in haemophilia A patients with and without inhibitors against factor VIII.

Poster presentation PB0325: Jonsson F, Schmitt C, Petry C, et al.

An Insight into the Impact of Hemophilia A on Daily Life According to Disease Severity: A Preliminary Analysis of the CHESS II Study.

Poster Presentation P-3449: Noone D, Nissen F, Xu T, et al.

Emicizumab prophylaxis improves long-term Physical Health Scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies.

Poster presentation PB0698: Skinner M, Negrier C, Paz-Priel I, et al.

Impact of Hemophilia A Inhibitor on Joint Health and Health-Related Quality of Life from the Hemophilia Utilization Group Studies Part VIII in the U.S

Poster Presentation P-3457: Ullman MM, Manco-Johnson MJ, Roberts JC, et al.

Early patient experiences with emicizumab in the United States: a qualitative study.

Poster presentation PB0244: Markowitz JT, Patel AM, Raimundo K, et al.

Health-Related Quality of Life in Paediatric Patients With Haemophilia A.

Poster presentation PB0250: Castro FA, Silkey M, Khair K, et al.

Treatment Patterns and Outcomes in Persons with Hemophilia A (PwHA): Analysis from the CHOICE Survey in the United States.

Poster presentation PB1404: Patel AM, Cyhaniuk A, Raimundo K, et al.

Expert Opinion on the UK Standard of Care for Haemophilia Patients with Inhibitors: A Delphi Consensus Study.

Poster presentation PB0708: Khair K, Chalmers E, Chowdary P, et al.

Evaluating Patient and Caregiver Treatment Preferences in Hemophilia A Using a Discrete Choice Experiment.

Poster presentation PB0245: Benton M, Shi L, Patel AM, et al.

Second Interim Analysis Results from the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial to Evaluate the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII Inhibitors.

Poster presentation PB0958: Jiménez-Yuste V, Klamroth R, Castaman G, et al.

Characteristics of persons with hemophilia A treated with emicizumab with or without factor VIII inhibitors.

Poster presentation #31: Mahajerin A, Yang E, Patel AM et al.

Bone and joint health markers in persons with hemophilia A (PwHA) treated with emicizumab in the HAVEN 3 clinical trial.

Poster presentation #36: Kiialainen A, Niggli M, Kempton C et al.

Summary of thrombotic or thrombotic microangiopathy events in persons with hemophilia A taking emicizumab.

Poster presentation #35: Lee L, Moreno K, Kuebler P et al.

An analysis of fatalities in persons with congenital hemophilia A reported in the FDA Adverse Event Reporting System (FAERS) database.

Poster presentation #25: De Ford C, Kuebler P, Shang A et al.

Real-world treatment patterns, health outcomes, and healthcare resource use among persons with hemophilia A.

Poster presentation #15: Caplan EO, Patel AM, DeClue R et al.

A systematic review of mortality statistics and causes of death in people with congenital hemophilia A (PwcHA).

Poster presentation #32: Hay CR, Nissen F, Pipe SW.

A contemporary framework for understanding mortality in people with congenital hemophilia A (PwcHA).

Poster presentation #23: Pipe SW, Kruse-Jarres R, Mahlangu JN et al.